The Gummy Project Announces Strategic Entry into the United States Retail Market with Hy-Vee as First Grocery Retailer

The Gummy Project Announces Strategic Entry into the United States Retail Market with Hy-Vee as First Grocery Retailer

The Gummy Project  (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce its entry into the U.S. market with Hy-Vee, Inc. as its first major retail partner.

The Gummy Project sells low-sugar, plant-based gummy products while raising money and awareness to support endangered species. For every bag of product purchased, GUMY donates a portion of the proceeds to help certain endangered species from going extinct.

"Hy-Vee is a great fit for The Gummy Project, being employee-owned and community-driven. There was an immediate connection around our "better-for-you" products and our mission centered around sustainability," said Mr. Charlie Lamb, President and CEO at GUMY.

Products from GUMY are anticipated to be in the candy aisles in more than 150 Hy-Vee stores later this year after being approved as a vendor on September 2, 2022. GUMY's U.S. expansion plans were accelerated after being selected as one of the most innovative new products at the Sweets & Snacks Expo in Chicago, Illinois earlier this year.

"Hy-Vee is a modern, relevant and engaging brand. We are absolutely thrilled to establish this partnership and excited about our entry into the U.S. market," said Anthony Gindin, CMO at GUMY. "We were lucky to have pitched to Hy-Vee on the Innovation stage in Chicago and it feels great to have made such an immediate connection around values that are important to both entities - bettering one's health, focusing on sustainability and improving the environment."

About Hy-Vee

Hy-Vee, Inc. is an employee-owned corporation operating more than 285 retail stores across eight Midwestern states with sales of more than $12 billion annually. The supermarket chain is synonymous with quality, variety, convenience, healthy lifestyles, culinary expertise and superior customer service. Hy-Vee ranks in the Top 5 Most Trusted Brands and has been named one of America's Top 3 favorite grocery stores. The company's more than 80,000 employees provide "A Helpful Smile in Every Aisle" to customers every day. For additional information, visit www.hy-vee.com.

About The Gummy Project

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow. https://shopgummies.com/

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free (877) 806-2633
E-mail: investors@shopgummies.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136302

News Provided by Newsfile via QuoteMedia

GUMY:CC
The Conversation (0)
The Gummy Project Enters State of Texas with Purchase Order from 5-star Luxury Hotel Located in Austin, Texas

The Gummy Project Enters State of Texas with Purchase Order from 5-star Luxury Hotel Located in Austin, Texas

  • Purchase Order from 5-star luxury hotel in Austin, Texas marks the achievement of another milestone in The Gummy Project's ongoing highly strategic multi-channel sales strategy
  • The Peachy Bees and Watermelon Sharks are expected to be for sale in each of the hotel's guest room private bars

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order for its Peachy Bees and Watermelon Sharks from a 5-star luxury hotel located in Austin, Texas (the "Luxury Hotel").

"Entering an additional US state and having our gummies for sale at this Luxury Hotel is another significant achievement for the Company as we continue to expand in both Canada and the US," said Charlie Lamb, President and CEO of GUMY.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Officially Launches in U.S. Market with Ecommerce Site and Nationwide Shipping

The Gummy Project Officially Launches in U.S. Market with Ecommerce Site and Nationwide Shipping

  • U.S. customers can now purchase Watermelon Sharks and Peachy Bees at www.shopgummies.com.
  • Product is shipped nationwide across the U.S. within 5-7 days.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce the official launch of its U.S. ecommerce site at www.shopgummies.com.

"We are excited to officially launch our products into the U.S. market, which is a major milestone for the company," said Charlie Lamb, CEO at GUMY. "We are now ready to ship product to all 50 states, which represents a tremendous growth opportunity for the Company beyond the existing Canadian market."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Warrant Repricing

The Gummy Project Announces Warrant Repricing

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") announces today that it has reduced the exercise price of 7,261,700 warrants (the "Amended Warrants") of the Company. All dollar figures are quoted in Canadian dollars.

The reduced exercise price is $0.05. The Amended Warrants include an accelerated expiry provision such that the exercise period of each of the Amended Warrants is reduced to 30 days if for any 10 consecutive trading days, the closing price of the Company's common shares is equal or greater than $0.05, with the 30-day expiry period commencing on the day the Company disseminates a press release announcing the commencement of the accelerated expiry period.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
CSE Bulletin: Consolidation - The Gummy Project Inc.

CSE Bulletin: Consolidation - The Gummy Project Inc.

 The Gummy Project Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 12,250,156 common shares.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation
maintained throughout the 26-week study

Episodes of pericarditis per year substantially reduced

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×